Active Ingredient History
JX-594 is an oncolytic virus is designed to target and destroy cancer cells. It is also known as Pexa-Vec, INN pexastimogene devacirepvec) and was constructed in Dr. Edmund Lattime's lab at Thomas Jefferson University, tested in clinical trials on melanoma patients, and licensed and further developed by SillaJen. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 1/Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Renal Cell (Phase 1)
Colorectal Neoplasms (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 1)
Lymphoma (Phase 1)
Melanoma (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 1/Phase 2)
Neuroblastoma (Phase 1)
Ovarian Neoplasms (Phase 2)
Rhabdomyosarcoma (Phase 1)
Sarcoma (Phase 1/Phase 2)
Sarcoma, Ewing (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Wilms Tumor (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue